Today: 11 June 2026
Browse Category

HKG:9688 24 December 2025 - 26 December 2025

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab shares were indicated around $18.58 premarket Friday, valuing the company near $2.1 billion. China approved COBENFY for schizophrenia on December 23, adding to recent company catalysts. U.S. markets reopen for a full session after the Christmas holiday, with thin liquidity and wider spreads expected. ZLAB’s 52-week range spans $16.82 to $44.34, with momentum indicators near oversold levels.
26 December 2025
···
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

China’s NMPA approved Zai Lab’s COBENFY for adult schizophrenia on Dec. 23, triggering a surge in Zai Lab shares. The U.S. ADR traded around $18.54 intraday, while Hong Kong shares closed at HK$14.48, up 6.24%. COBENFY is the first M1/M4 muscarinic receptor therapy for schizophrenia approved in China. Zai Lab holds exclusive commercialization rights in Greater China.
24 December 2025
···

Stock Market Today

  • What is an IPO as SpaceX Prepares for U.S. Stock Market Debut
    June 10, 2026, 6:01 PM EDT. An IPO, or Initial Public Offering, is when a private company sells shares to the public for the first time, becoming publicly traded. SpaceX, the aerospace manufacturer, is expected to make its debut on the U.S. stock market, marking one of the most anticipated IPOs in recent years. This move allows retail and institutional investors to buy equity in SpaceX, potentially impacting the space industry and tech sectors. The IPO process involves regulatory filings, pricing, and public trading, providing companies with capital for expansion. SpaceX's offering could reshape market dynamics, drawing significant investor interest given its innovations and growth trajectory.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Go toTop